The CCDC117 Knockout HAP1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population designed to disrupt the CCDC117 gene in the HAP1 human cell line. This product comprises a heterogeneous pool of cells carrying diverse mutations introduced at the CCDC117 locus by CRISPR/Cas9, collectively resulting in loss of gene function at the population level. The polyclonal format avoids the selection bias and clonal artifacts often associated with single-cell-derived knockouts, ensuring robust and reproducible loss-of-function phenotypes. It is provided as a living culture ready for expansion and downstream applications.
The parental HAP1 cell line is a near-haploid human cell line originating from the KBM-7 chronic myeloid leukemia (CML) line. Its predominantly haploid genome means that a single CRISPR-mediated mutation can completely abrogate gene function, greatly simplifying genotype?Cphenotype correlations. HAP1 cells express the BCR-ABL1 fusion oncogene, which drives their proliferation and survival, and are widely used as a hematopoietic progenitor model in cancer biology, drug sensitivity profiling, and functional genomic screens.
CCDC117 encodes a coiled-coil domain-containing protein of unknown biological function. Coiled-coil domains are established mediators of protein?Cprotein interactions, often facilitating the assembly of oligomeric complexes and serving as scaffolds in signal transduction pathways. Although no upstream regulators, downstream targets, or interacting partners have been identified for CCDC117, its domain architecture implies a role in intracellular protein networks. Disrupting CCDC117 in this knockout model likely ablates its capacity to engage in such interactions, providing a powerful system to investigate its functional role.
In the HAP1 leukemia background, CCDC117 knockout offers a clean genetic model to study its potential involvement in hematopoietic cell biology and oncogenic processes. The haploid karyotype allows unambiguous assessment of knockout effects on cellular phenotypes such as proliferation, apoptosis, and drug responsiveness. This tool may help determine whether CCDC117 modulates BCR-ABL1-driven signaling or operates in parallel pathways, and its polyclonal nature makes it suitable for pooled screening approaches to uncover genetic interactions.
This polyclonal knockout cell pool is suitable for a range of applications, including functional genomics, genetic screening, and de novo characterization of unannotated genes. Representative assays include Western blotting to confirm protein depletion, RT-qPCR to quantify transcript levels, and phenotypic tests such as proliferation, apoptosis, and drug sensitivity analysis. For further information, technical support, or custom requests, please contact Ascent Research.
